Phathom Pharmaceuticals Inc (NASDAQ/NGS (GLOBAL SELECT MARKET):PHAT)

Expected performance: Start your 30-days free trial
About the company

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.

Exchange

NASDAQ/NGS (GLOBAL SELECT MARKET)

Website

www.phathompharma.com

$NoneM

Total Revenue

55

Employees

$1B

Market Capitalization

-7.61

Price/Earning ratio

Stock price

Gross Margin (%)

Total gross margin

Operating Margin (%)

Total operating margin

Net Margin (%)

Total net margin

Dividend Yield (%)

Dividend per share

$0

90-days Stock Price Forecast (%)

PREDICT MONTHLY

$29.9 / Month

  • 4000+ Daily forecasts
  • Company fundamentals
  • Follow list
  • Industry leaderboard
  • Portfolio optimization
  • Billed monthly
  • Cancel anytime

OPTIMIZE YEARLY

$479.9 / Year

  • 4000+ Daily forecasts
  • Company fundamentals
  • Follow list
  • Industry leaderboard
  • Portfolio optimization
  • Billed yearly
  • Cancel anytime

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (%)
Conversion Labs Inc CVLB 108548.37 35213.00 3.74 42.66 7.33
Royalty Pharma plc RPRX 23187.40 2195.00 4.75 43.41 24.23
Organon & Co. OGN 7339.53 7822.00 1.56 3.96 23.73
Arvinas Inc ARVN 4246.20 21.00 8.07 -30.64 -656.62
Cronos Group Inc CRON 2616.35 51.00 1.74 -8.47 -610.02
ATAI Life Sciences N.V. ATAI 2371.50 20.00 21.23 -12.81 -932.88
Tilray Inc TLRY 2144.52 210.00 8.18 -7.92 -128.79
Usana Health Sciences Inc USNA 2000.67 1176.00 4.79 15.67 10.95
Phathom Pharmaceuticals Inc PHAT 1091.40 None 6.11 -7.61 None
Phibro Animal Health Corp. PAHC 970.47 799.00 4.44 22.33 5.37
Edgewise Therapeutics Inc EWTX 857.99 None 2.82 -41.69 None
Intersect ENT Inc XENT 770.55 85.00 14.78 -10.20 -87.96
Pliant Therapeutics Inc PLRX 727.20 15.00 2.74 -11.22 -427.75
Chromadex Corp CDXC 538.78 60.00 13.37 -24.83 -35.92
Urovant Sciences Ltd UROV 503.44 None -3.65 -3.08 None
Rain Therapeutics Inc RAIN 432.90 None -10.03 -17.16 None
Evolus Inc EOLS 389.52 58.00 25.16 -2.65 -234.84
Cyteir Therapeutics Inc CYT 365.75 None -12.18 -17.04 None
Ikena Oncology Inc IKNA 356.76 9.00 1.56 -7.56 -498.11
Provention Bio Inc PRVB 339.92 None 2.09 -2.84 None
Verrica Pharmaceuticals Inc VRCA 267.50 12.00 4.73 -7.87 -281.73
LifeMD Inc LFMD 255.06 51.00 -31.65 -2.09 -141.77
Adicet Bio Inc ACET 236.80 12.00 1.00 -4.40 -448.84
Osmotica Pharmaceuticals Plc OSMT 206.46 153.00 2.45 -2.36 -56.24
Fulcrum Therapeutics Inc FULC 204.68 13.00 1.87 -2.90 -539.31
Kala Pharmaceuticals Inc KALA 200.10 9.00 2.03 -1.78 None
Kaleido Biosciences Inc KLDO 195.48 1.00 3.21 -2.28 None
Milestone Pharmaceuticals Inc MIST 193.80 None 1.29 -4.29 None
Terns Pharmaceuticals Inc TERN 187.50 None 0.99 -5.56 None
Longboard Pharmaceuticals Inc LBPH 153.00 None 1.29 -7.50 None
scPharmaceuticals Inc SCPH 142.48 119.00 1.99 -4.49 -27.05
Eton Pharmaceuticals Inc ETON 118.22 12.00 5.84 -8.03 -116.63
Odonate Therapeutics Inc ODT 116.90 None 1.22 -0.89 None
Citius Pharmaceuticals Inc CTXR 115.29 None 2.20 -5.73 None
VYNE Therapeutics Inc VYNE 113.40 23.00 1.49 -0.60 -483.51
Aquestive Therapeutics Inc AQST 110.50 48.00 -2.29 -2.06 -111.86
Natural Alternatives International, Inc. NAII 106.26 169.00 1.50 11.97 5.68
Eyenovia Inc EYEN 97.29 4.00 9.00 -5.04 -491.77
Aerpio Pharmaceuticals Inc ARPO 88.88 15.00 2.46 -22.44 -32.26
India Globalization Capital Inc IGC 74.34 1.00 2.60 -8.43 -981.18
Opiant Pharmaceuticals Inc OPNT 64.48 32.00 2.05 -23.03 -9.52
Acasti Pharma Inc ACST 54.74 0.00 1.70 -2.71 -611.47
Mannatech Inc MTEX 52.62 153.00 2.06 9.89 3.70
Assertio Holdings Inc ASRT 39.06 112.00 0.52 -0.42 -57.78
Trevi Therapeutics Inc TRVI 34.20 None 1.73 -1.08 None
Bio-Path Holdings Inc BPTH 25.60 0.00 1.42 -2.71 18.96
Lexaria Bioscience Corp LEXX 24.92 1.00 3.07 -6.36 -445.15
Baudax Bio Inc BXRX 20.13 1.00 -61.00 -3.59 None
Nabriva Therapeutics Plc NBRV 18.70 5.00 0.99 -0.32 None
Cyanotech Corp. CYAN 18.36 32.00 1.10 20.40 2.84
Hoth Therapeutics Inc HOTH 18.06 None 1.54 -2.02 None
Reviva Pharmaceuticals Holdings Inc. RVPH 17.50 None 13.46 -3.27 None
Timber Pharmaceuticals Inc TMBR 15.68 None 6.13 -1.01 None
Sonoma Pharmaceuticals Inc. SNOA 13.42 19.00 2.62 -3.41 -21.20
Shineco Inc TYHT 11.88 14.00 0.61 -0.58 -159.60

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Were Hedge Funds Right About Phathom Pharmaceuticals, Inc. (PHAT)?

5d ago, source: YAHOO!Finance

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in ...

Phathom Pharmaceuticals Inc

1mon ago, source: U.S. News & World Report

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. Its product ...

BRIEF-Phathom Pharmaceuticals Inc Says On July 2, 2021, Entered Into A Commercial Supply Agreement With Catalent Pharma Solutions Llc

23d ago, source: MSN

July 8 (Reuters) - Phathom Pharmaceuticals Inc: * PHATHOM PHARMACEUTICALS INC - ON JULY 2, 2021, ENTERED INTO A COMMERCIAL SUPPLY AGREEMENT WITH CATALENT PHARMA SOLUTIONS, LLC * PHATHOM ...

Phathom Pharmaceuticals Inc Ordinary shares PHAT

10d ago, source: Morningstar%2c Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

19d ago, source: Yahoo Finance

The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC ...

Phathom Pharmaceuticals Inc.

11d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

19d ago, source: Business Wire

The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC ...

Your Portfolio

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.